{"schema_version":"secwatch.filing_event.v1","accession":"0001739410-24-000053","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.834816+00:00","generated_at":"2026-06-02T06:32:40.791799+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Rallybio posts Q1 net loss of $19.0M; cash $94.2M; on track for RLYB212 Phase 2 in 2H 2024","bullets":["Net loss of $19.0M ($0.47 per share) vs $17.3M ($0.43 per share) in Q1 2023.","Cash, cash equivalents, and marketable securities of $94.2M as of March 31, 2024; runway into mid-2026.","Announced 45% workforce reduction in Feb 2024 to focus on RLYB212 and RLYB116.","Collaboration with Johnson & Johnson (Momenta) for FNAIT; received $6.6M equity investment.","Phase 2 trial of RLYB212 in pregnant women at risk for FNAIT on track for 2H 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001739410-24-000053","json":"https://secwatch.observer/filing/0001739410-24-000053.json","markdown":"https://secwatch.observer/filing/0001739410-24-000053.md","text":"https://secwatch.observer/filing/0001739410-24-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000053/0001739410-24-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000053/rlyb-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:32:40.791799+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2869a78a5fff0e942dd40121ddfadb137b6efbc7","claim":"Rallybio Corp reported financial results for the quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, Rallybio Corporation issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739410/000173941024000053/0001739410-24-000053-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}